Metal Abstraction Peptide (MAP) Tag and Associated Methods
Compositions comprising a tripeptide having the sequence XC 1 C 2 ; wherein X is any amino acid such that XC 1 C 2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C 1 and C 2 are the same or different; and wherein C 1 and C 2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC 1 C 2 complexes and methods for forming such complexes.
1 . A method of providing chelation therapy to a patient in need thereof comprising administering to said patient a composition comprising a peptide including a sequence XC 1 C 2 ,
wherein X is any natural or non-natural amino acid or amino acid analog,
and further wherein C 1 and C 2 are each individually chosen from a cysteine and a sulfur-containing alpha or beta amino acid;
wherein said peptide binds to a metal atom or ion in said patient.
2 . The method of claim 1 , wherein said peptide is included in the sequence Z—XC 1 C 2 —Z 1 , wherein Z and Z 1 are each individually any natural or non-natural amino acid or sequence of natural or non-natural amino acids.
3 . The method of claim 1 , wherein said peptide is included in the sequence Z—XC 1 C 2 , wherein Z is any natural or non-natural amino acid or sequence of natural or non-natural amino acids.
4 . The method of claim 1 , wherein said peptide is included in the sequence XC 1 C 2 —Z 1 , wherein Z 1 is any natural or non-natural amino acid or sequence of natural or non-natural amino acids.
5 . The method of claim 1 , wherein said peptide is linked to a polypeptide, an antibody, a growth factor, or a carbohydrate.
6 . The method of claim 1 , wherein the metal atom or ion is bound in a square planar or square pyramidal orientation.
7 . The method of claim 1 , wherein said metal is present in said patient in a biologically toxic concentration.
8 . The method of claim 1 , wherein said metal is selected from the group consisting of a Group 3 metal, a Group 5 metal, a Group 6 metal, a Group 7 metal, a Group 8 metal, a Group 9 metal, a Group 10 metal, a Group 11 metal, a Group 12 metal, a Group 13 metal, a Group 14 metal, and a Group 15 metal.
9 . The method of claim 8 , wherein said metal is selected from the group consisting of a Group 5, Group 6, Group 12, and Group 14 metal.
10 . The method of claim 9 , wherein said metal is selected from the group of Group 6 metals consisting of Cr and Mo.
11 . The method of claim 10 , wherein said metal is Cr.
12 . The method of claim 9 , wherein said metal is selected from the group of Group 12 metals consisting of Cd and Hg.
13 . The method of claim 12 , wherein said metal is Hg.
14 . The method of claim 9 , wherein said metal is selected from the group of Group 14 metals consisting of Sn and Pb.
15 . The method of claim 14 , wherein said metal is Pb.
16 . The method of claim 1 , wherein C 1 and C 2 are each cysteine.
17 . The method of claim 1 , wherein X is chosen from asparagine, glutamine, histidine, lysine, and arginine.
18 . The method of claim 1 , wherein said composition is formulated for in vivo administration.
19 . The method of claim 18 , wherein said composition is formulated for in vivo administration to a human.
20 . A composition for providing chelation therapy to a patient in need thereof according to the method of claim 1 , said composition comprising a peptide including a sequence XC 1 C 2 ; wherein said peptide binds to a metal atom or ion in vivo.